Document is current
Any future updates will be listed below
-
Authors
Wise, David R. https://orcid.org/0000-0003-3419-4723
Pachynski, Russell K.
Denmeade, Samuel R.
Aggarwal, Rahul R. https://orcid.org/0000-0001-7003-7982
Deng, Jiehui https://orcid.org/0000-0001-7986-8643
Febles, Victor Adorno https://orcid.org/0000-0003-4386-3490
Balar, Arjun V.
Economides, Minas P.
Loomis, Cynthia
Selvaraj, Shanmugapriya https://orcid.org/0000-0003-1718-0282
Haas, Michael
Kagey, Michael H.
Newman, Walter
Baum, Jason
Troxel, Andrea B.
Griglun, Sarah
Leis, Dayna
Yang, Nina
Aranchiy, Viktoriya
Machado, Sabrina
Waalkes, Erika
Gargano, Gabrielle
Soamchand, Nadia
Puranik, Amrutesh
Chattopadhyay, Pratip
Fedal, Ezeddin
Deng, Fang-Ming
Ren, Qinghu
Chiriboga, Luis
Melamed, Jonathan https://orcid.org/0000-0003-2844-7990
Sirard, Cynthia A. https://orcid.org/0000-0003-4856-4457
Wong, Kwok-Kin
- License Information
-
More Information
Article History
Received: 31 July 2023
Revised: 16 January 2024
Accepted: 22 January 2024
First Online: 10 February 2024
Competing interests
: DRW is a paid consultant for Leap Therapeutics, Foundation Medicine, Pfizer, Janssen, Sanofi, Lilly, Labcorp, Myovant, Bayer, AstraZeneca, Accutar. He has received travel funding from Pfizer and Bayer.
